Greenspan Em
About
In The Last Decade
Greenspan Em
18 papers receiving 299 citations
Peers
Comparison fields: 5 of 80
- Oncology 155
- Molecular Biology 69
- Cancer Research 67
- Pathology and Forensic Medicine 64
- Surgery 51
Countries citing papers authored by Greenspan Em
This map shows the geographic impact of Greenspan Em's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greenspan Em with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greenspan Em more than expected).
Fields of papers citing papers by Greenspan Em
This network shows the impact of papers produced by Greenspan Em. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greenspan Em. The network helps show where Greenspan Em may publish in the future.
Co-authorship network of co-authors of Greenspan Em
This figure shows the co-authorship network connecting the top 25 collaborators of Greenspan Em. A scholar is included among the top collaborators of Greenspan Em based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greenspan Em. Greenspan Em is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | The effect of hepatobiliary diseases on the serum acid precipitable globulin (APG) turbidity. | 0 |
| 2 | The acid precipitable globulin (APG) turbidity: a convenient guide to the status of serum alpha-2 plus beta globulins. | 0 |
| 3 | Some theoretical and practical aspects of the use of folic acid antagonists in human neoplasia. | 0 |
| 4 | A clinical survey of globulin distribution patterns determined by simple in vitro laboratory methods. | 0 |
| 5 | Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA. | 12 |
| 6 | Combination chemotherapy of advanced ovarian carcinoma with the antimetabolite, methotrexate, and the alkylating agent, thioTEPA. | 2 |
| 7 | Phase I study of m-AMSA in patients with solid tumors and leukemias. | 8 |
| 8 | Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy. | 43 |
| 9 | Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy. | 27 |
| 10 | Comparison of regression induction with triethylenethiophosphoramide or methotrexate in bulky stage IIIb ovarian carcinoma. | 1 |
| 11 | Combination chemotherapy for advanced mammary carcinoma: a twelve-year experience. | 10 |
| 12 | 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) given alone and combined with antimetabolites in the treatment of advanced solid tumors. | 1 |
| 13 | Thio-TEPA and methotrexate chemotherapy of advanced ovarian carcinoma. | 12 |
| 14 | Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. | 63 |
| 15 | REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU. | 4 |
| 16 | Angiosarcoma responsive to cyclophosphamide after failure of the combination of thio TEPA and methotrexate. | 4 |
| 17 | Isolation-perfusion in cancer chemotherapy, current status and preliminary experiences. | 2 |
| 18 | Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists. | 87 |
| 19 | The serum mucoproteins as an aid in the differentiation of neoplastic from primary parenchymatous liver disease. | 38 |
| 20 | Estimation of nonglucosamine polysaccharides of the serum proteins with the anthrone reagent. | 35 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.